The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

The stock's fall snapped a four-day winning streak.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

I'm in London, and I just paid for this damn fat drug I take. I said, it's not working. They said, he said, I just paid $88 ...

BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is ...

This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

The Vanguard Growth ETF ( VUG 0.85%) doesn't just beat the market -- it demolishes it. A $10,000 investment at its 2004 ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...